Jazz Pharmaceuticals has successfully acquired and integrated Chimerix, marking a significant step in its corporate development strategy. The acquisition includes the Phase 3 ACTION trial, with Modeyso approval granted ahead of schedule. Early launch results have been strong, delivering nearly $50 million in revenue for 2025, with ongoing enrollment and interim overall survival data expected in late 2026 or early 2027. The company also highlighted potential international expansion opportunities and reported that the transaction is expected to reduce future cash taxes by approximately $200 million through a deferred tax asset. In addition, a definitive agreement has been executed to sell a Priority Review Voucher for $200 million in gross proceeds. The new asset is viewed as having a peak sales potential exceeding $500 million.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Jazz Pharmaceuticals plc published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001193125-26-009899), on January 12, 2026, and is solely responsible for the information contained therein.